Valeritas Announces Reverse Stock Split

3/14/17

BRIDGEWATER, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (OTCQB:VLRX) today announced that effective at 9:00 a.m., EDT, on March 15, 2017, the Company will effect an eight-for-one reverse stock split of its outstanding common stock. The authority to implement a reverse stock split was approved by the Company's stockholders at the Special Meeting of Stockholders held on March 8, 2017, and the Company’s Board of Directors subsequently adopted the reverse stock split. Upon the effectiveness of the reverse stock split, every eight shares of issued and outstanding common stock as of the close of business on March 14, 2017 will be combined into one issued and outstanding share of common stock, with no change in par value per share. The Company's common stock will open for trading on the OTCQB on March 15, 2017 on a post-split basis.

The reverse stock split is primarily intended to bring the Company into compliance with the minimum average closing share price requirement for its potential up-listing onto the Nasdaq Capital Market. The Company's common stock will continue to trade under the symbol "VLRX" but will have a new CUSIP number (91914N 202).

The reverse stock split will reduce the number of shares of the Company's outstanding common stock from approximately 13.1 million shares to approximately 1.6 million shares. No fractional shares will be issued as a result of the reverse stock split. Any fractional shares that would result from the reverse stock split will be settled in cash. Shareholders holding share certificates will receive information from West Coast Stock Transfer, the Company's transfer agent, regarding the process for exchanging their shares of common stock.

Additional information about the reverse stock split can be found in the Company's proxy statement filed with the Securities and Exchange Commission on February 15, 2017, a copy of which is available at www.sec.gov.

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.